Other Agreements - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock	600,000
Remaining cash consideration to be paid	$ 15,000,000
Percentage on annual revenues for cash consideration to be paid	6.00%
Discount rate used to calculate asset purchase obligation	2.50%
Unamortized debt discount	709,822
Payments on obligation	0	425,000
Accretion of discount on Nuvogen obligation	126,566	47,500
Research and development	688,214	857,483
Agreement expiration date	Oct. 31, 2019
Description on termination of agreement	The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000
Research and development	0
Growth Term Loan
Other Agreements [Line Items]
Minimum payments of pledged intangible assets due in 2014	868,750
Minimum payments of pledged intangible assets due in 2015	868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	0
Nuvogen
Other Agreements [Line Items]
Unamortized debt discount	$ 438,067		$ 564,634